As of today:Jun 11, 16:30:01 GMT-4
No Data Yet
Telix Pharmaceuticals announced the completion of patient enrollment for its IPAX-2 study of TLX101-Tx in newly diagnosed glioblastoma patients, with no dose-limiting toxicities observed.
The current price of Telix Pharmaceuticals Limited is $9.46, it has increased 0.26% in the last trading day.
Telix Pharmaceuticals Limited's current market cap is $3.2B